I'm LongbridgeAI, I can summarize articles.Hong Kong's overlooked equities are carving divergent paths amid broader market stagnation. Evergreen MedSci (1952.HK) surged 8% intraday after recruiting key architects of Moderna's mRNA-4157 cancer vaccine, positioning its self-owned platform as a rare China-based alternative in the global mRNA race. The move comes as CRRC (1766.HK) gains momentum from its Mexican rail contract, with new energy segment revenues jumping 62.63% sequentially in Q2 2026.
Meanwhile, Joyson Electronics (0699.HK) exemplifies the robotics supply chain spillover effect—its Hong Kong shares spiked 10% when Tesla initiated Optimus production audits in Ningbo, though profit-taking erased most gains by week's end. Asymchem (6821.HK) tells a contrasting story: despite Goldman Sachs' upbeat CDMO sector forecast, the stock plunged 11.85% following regulatory concerns over export controls on biotech know-how.
Traditional sectors show stark contrasts. Energy & Power Global (1142.HK) saw volatile swings after its 10-for-1 share consolidation, while Wanhui Technology (0894.HK) tumbled 19% amid passive component demand slump. Zhonghui Group (0382.HK) reported declining domestic education revenue but 24.25% overseas growth, and Tongtian Winery (0389.HK) posted 47.58% annual revenue growth despite wine industry headwinds.
